Amicus Therapeutics, Inc. (FOLD) is a Biotechnology company in the Healthcare sector, currently trading at $14.46. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of FOLD = $62.51 (+332.3% from the current price, the stock appears undervalued). Analyst consensus target is FOLD = $15 (+0.3% upside).
Valuation: FOLD trades at a trailing Price-to-Earnings (P/E) of -164.8 (S&P 500 average ~25).
Financials: revenue is $634M, +24.5%/yr average growth. Net income is $27M (loss), growing at +50.2%/yr. Net profit margin is -4.3% (negative). Gross margin is 87.3% (-1 pp trend).
Balance sheet: total debt is $483M against $274M equity (Debt-to-Equity (D/E) ratio 1.76, leveraged). Current ratio is 2.84 (strong liquidity). Debt-to-assets is 50.9%. Total assets: $950M.
Analyst outlook: 16 / 24 analysts rate FOLD as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 100/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 66/100 (Partial), Future 55/100 (Partial), Income 10/100 (Fail).
